1. Kazemian P, Oudit G, Jugdutt BI. Atrial fibrillation and heart failure in the elderly. Heart Fail Rev 2012;17:597–613.
3. Karnik AA, Gopal DM, Ko D, Benjamin EJ, Helm RH. Epidemiology of atrial fibrillation and heart failure: a growing and important problem. Cardiol Clin 2019;37:119–29.
4. Laothavorn P, Hengrussamee K, Kanjanavanit R, Moleerergpoom W, Laorakpongse D, Pachirat O, et al. Thai acute decompensated heart failure registry (Thai ADHERE). CVD Prev Control 2010;5:89–95.
5. Phrommintikul A, Detnuntarat P, Prasertwitayakij N, Wongcharoen W. Prevalence of atrial fibrillation in Thai elderly. J Geriatr Cardiol 2016;13:270–3.
7. Buakhamsri A, Chirakarnjanakorn S, Sanguanwong S, Porapakkham P, Kanjanavanich R. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: pharmacologic treatment of chronic heart failure-part I. J Med Assoc Thai 2019;102:240–4.
8. Yingchoncharoen T, Kanjanavanich R. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: pharmacologic treatment of chronic heart failure-part II. J Med Assoc Thai 2019;102:368–72.
9. Chantrarat T, Kunjara Na Ayudhya R, Phrominthikul A, Ariyachaipanich A, Krittayaphong R. Heart Failure Council of Thailand (HFCT) 2019 heart failure guideline: atrial fibrillation in heart failure guidelines. J Med Assoc Thai 2019;102:513–7.
10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.
11. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498.
12. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015;44:213–8.
13. Singh S, Moore H, Karasik PE, Lam PH, Wopperer S, Arundel C, et al. Digoxin initiation and outcomes in patients with heart failure (HFrEF and HFpEF) and atrial fibrillation. Am J Med 2020;133:1460–70.
14. Gao Y, Chang S, Du X, Dong J, Xu X, Zhou Y, et al. Association between digoxin use and adverse outcomes among patients in the Chinese atrial fibrillation registry. Am J Cardiovasc Drugs 2019;19:579–87.
15. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525–33.
16. Rich MW, McSherry F, Williford WO; Yusuf S; Digitalis Investigation Group. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol 2001;38:806–13.
17. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, et al. Increased mortality among patients taking digoxin: analysis from the AFFIRM study. Eur Heart J 2013;34:1481–8.
18. Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:1063–74.
19. Elayi CS, Shohoudi A, Moodie E, Etaee F, Guglin M, Roy D, et al. Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: an AF-CHF analysis. Int J Cardiol 2020;313:48–54.
23. Al-Zakwani I, Panduranga P, Zubaid M, Sulaiman K, Rashed WA, Alsheikh-Ali AA, et al. Impact of digoxin on mortality in patients with atrial fibrillation stratified by heart failure: findings from gulf survey of atrial fibrillation events in the middle east. J Cardiovasc Pharmacol Ther 2016;21:273–9.
25. Qamer SZ, Malik A, Bayoumi E, Lam PH, Singh S, Packer M, et al. Digoxin use and outcomes in patients with heart failure with reduced ejection fraction. Am J Med 2019;132:1311–9.
26. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol 2014;30:1190–5.
28. Knodel J, Chayovan N. Older persons in Thailand: a demographic, social and economic profile. Ageing Int 2008;33:3–14.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83.
30. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–9.
31. Jenghua K, Jedsadayanmata A. Rate and predictors of early readmission among Thai patients with heart failure. J Med Assoc Thai 2011;94:782–8.
32. Senaviratna NAMR, A. Cooray TMJ. Diagnosing multicollinearity of logistic regression model. Asian J Probab Stat 2019;5:1–9.
33. Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Crit Pathw Cardiol 2011;10:93–8.
34. Pandya L, Brown DL. The association of digoxin with mortality in ischemic heart failure: a secondary analysis of the STICH trial. Eur Heart J 2020;41(Suppl_2):ehaa946-0882.